Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

So before I hand over to Paul ... But more importantly, I remember being here last year after we just changed our guidance and renewed our vows with science, that there was some raised eyebrows.

This includes medicated creams and pills, dupilumab (Dupixent ... the skin becomes inflamed and may itch more than before. While eczema’s cause is not known, it may stem from both environmental ...

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two ... are allergic to dupilumab or to any of the ingredients in DUPIXENT®. Before using DUPIXENT ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab ... But three years after buying Ziarco for an undisclosed sum, Novartis said the phase 2 drug ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing ... of patent life left before it could face ...

The median age was 15.8 years (IQR 9.3–19.5 years) and all patients had already failed conventional therapy Indeed, before dupilumab initiation, the median peak esophageal eosinophil count at biopsies ...

Odronextamab is approved in the European Union as Ordspono™ to treat R/R FL or DLBCL after two or more lines ... Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.